ticlopidine has been researched along with vinpocetine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, M; Andoh, S; Hasegawa, T; Monzen, H; Suzuki, M; Terai, K; Tsumuraya, A | 1 |
| Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W | 1 |
1 trial(s) available for ticlopidine and vinpocetine
| Article | Year |
|---|---|
Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Circulation; China; Clopidogrel; Cognition; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Platelet Aggregation Inhibitors; Quality of Life; Stroke; Ticlopidine; Ultrasonography, Doppler, Transcranial; Vinca Alkaloids | 2016 |
1 other study(ies) available for ticlopidine and vinpocetine
| Article | Year |
|---|---|
Increase in tumor oxygenation and potentiation of radiation effects using pentoxifylline, vinpocetine and ticlopidine hydrochloride.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Mice; Mice, Inbred C3H; Oxidative Stress; Oxygen; Pentoxifylline; Radiation Tolerance; Radiation-Sensitizing Agents; Ticlopidine; Treatment Outcome; Vinca Alkaloids | 2005 |